Clinical trials: pMMR
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT04221555
- Testing
- Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center